NEW YORK (GenomeWeb News) – Translational life science tools and molecular diagnostics company NanoString Technologies today filed for an initial public offering.

In its Form S-1 filed with the US Securities and Exchange Commission, the Seattle-based company said it anticipates a proposed maximum aggregate offering price of about $86.3 million, but did not provide a price range for its shares or the amount of shares to be sold.

JP Morgan and Morgan Stanley will be joint book-running managers for the offering, and Leerink Swann and R.W. Baird will act as co-managers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.